AAAAAA

   
Results: 1-14 |
Results: 14
Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase
Authors: Giles, FJ Kantarjian, H O'Brien, S Rios, MB Cortes, J Beran, M Koller, C Keating, M Talpaz, M
Citation: Fj. Giles et al., Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase, LEUK LYMPH, 41(3-4), 2001, pp. 309-319
Response to therapy is independently associated with survival prolongationin chronic myelogenous leukemia in the blastic phase
Authors: Kantarjian, HM Shan, JQ Smith, T Talpaz, M Kozuch, P Rios, MB Cortes, J Giles, FJ O'Brien, S
Citation: Hm. Kantarjian et al., Response to therapy is independently associated with survival prolongationin chronic myelogenous leukemia in the blastic phase, CANCER, 92(10), 2001, pp. 2501-2507
Expression of apoptosis proteins in chronic myelogenous leukemia - Associations and significance
Authors: Ravandi, F Kantarjian, HM Talpaz, M O'Brien, S Faderl, S Giles, FJ Thomas, D Cortes, J Andreeff, M Estrov, Z Rios, MB Albitar, M
Citation: F. Ravandi et al., Expression of apoptosis proteins in chronic myelogenous leukemia - Associations and significance, CANCER, 91(11), 2001, pp. 1964-1972
Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia
Authors: Rodriguez, J Cortes, J Talpaz, M O'Brien, S Smith, TL Rios, MB Kantarjian, H
Citation: J. Rodriguez et al., Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia, CLIN CANC R, 6(1), 2000, pp. 147-152
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia
Authors: Kantarjian, HM Talpaz, M Smith, TL Cortes, J Giles, FJ Rios, MB Mallard, S Gajewski, A Murgo, A Cheson, B O'Brien, S
Citation: Hm. Kantarjian et al., Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia, J CL ONCOL, 18(20), 2000, pp. 3513-3521
Significance of FHIT expression in chronic myelogenous leukemia
Authors: Kantarjian, HM Talpaz, M O'Brien, S Manshouri, T Cortes, J Giles, F Rios, MB Croce, CM Albitar, M
Citation: Hm. Kantarjian et al., Significance of FHIT expression in chronic myelogenous leukemia, CLIN CANC R, 5(12), 1999, pp. 4059-4064
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia
Authors: Sacchi, S Kantarjian, HM Freireich, EJ O'Brien, SO Cortes, J Rios, MB Kornblau, S Giles, FJ Koller, C Gajewski, J Talpaz, M
Citation: S. Sacchi et al., Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia, LEUK LYMPH, 35(5-6), 1999, pp. 483-489
Phase I study of arabinosyl-5-azacytidine (Fazarabine) in adult acute leukemia and chronic myelogenous leukemia in elastic phase
Authors: Wilhelm, M O'Brien, S Rios, MB Estey, E Keating, MJ Plunkett, W Sorenson, M Kantarjian, HM
Citation: M. Wilhelm et al., Phase I study of arabinosyl-5-azacytidine (Fazarabine) in adult acute leukemia and chronic myelogenous leukemia in elastic phase, LEUK LYMPH, 34(5-6), 1999, pp. 511-518
Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization
Authors: Seong, D Kantarjian, HM Albitar, M Arlinghaus, R Xu, J Talpaz, M Rios, MB Guo, JQ O'Brien, S Siciliano, M
Citation: D. Seong et al., Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization, ANN ONCOL, 10(8), 1999, pp. 955-959
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine
Authors: Kantarjian, HM O'Brien, S Smith, TL Rios, MB Cortes, J Beran, M Koller, C Giles, FJ Andreeff, M Kornblau, S Giralt, S Keating, MJ Talpaz, M
Citation: Hm. Kantarjian et al., Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine, J CL ONCOL, 17(1), 1999, pp. 284-292
Chronic myelogenous leukemia in nonlymphoid blastic phase - Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
Authors: Sacchi, S Kantarjian, HM O'Brien, S Cortes, J Rios, MB Giles, FJ Beran, M Koller, CA Keating, MJ Talpaz, M
Citation: S. Sacchi et al., Chronic myelogenous leukemia in nonlymphoid blastic phase - Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients, CANCER, 86(12), 1999, pp. 2632-2641
A Phase I-II trial of escalating doses of mitoxantrone with fixed doses ofcytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia
Authors: Koller, CA Kantarjian, HM Feldman, EJ O'Brien, S Rios, MB Estey, E Keating, M
Citation: Ca. Koller et al., A Phase I-II trial of escalating doses of mitoxantrone with fixed doses ofcytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia, CANCER, 86(11), 1999, pp. 2246-2251
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia
Authors: O'Brien, S Kantarjian, H Koller, C Feldman, E Beran, M Andreeff, M Giralt, S Cheson, B Keating, M Freireich, E Rios, MB Talpaz, M
Citation: S. O'Brien et al., Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia, BLOOD, 93(12), 1999, pp. 4149-4153
Determinants of prognosis in late chronic-phase chronic myelogenous leukemia
Authors: Rodriguez, J Cortes, J Smith, T O'Brien, S Rios, MB Talpaz, M Kantarjian, H
Citation: J. Rodriguez et al., Determinants of prognosis in late chronic-phase chronic myelogenous leukemia, J CL ONCOL, 16(12), 1998, pp. 3782-3787
Risultati: 1-14 |